ScholarIQanswers from OpenAlex & ORCID
James G. Krueger
ResearcherPublications, citations & collaboration network
James G. Krueger is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does James G. Krueger have?
ScholarIQindexed works
James G. Krueger has 742 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does James G. Krueger have?
ScholarIQcitation count
James G. Krueger has 69,078 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of James G. Krueger?
ScholarIQh-index
James G. Krueger has an h-index of 143 in OpenAlex.
What is the i10-index of James G. Krueger?
ScholarIQi10-index
James G. Krueger has an i10-index of 452 in OpenAlex.
What is the ORCID of James G. Krueger?
ScholarIQorcid
The ORCID for James G. Krueger is on the source record.
What is the OpenAlex record for James G. Krueger?
ScholarIQopenalex
The OpenAlex for James G. Krueger is on the source record.
What are the most-cited papers on James G. Krueger?
ScholarIQmost cited works
Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
Batya B. Davidovici, Naveed Sattar, Prinz C. Jörg, L. Puig, Paul Emery, Jonathan N. Barker, Peter van de Kerkhof, Mona Ståhle, Frank O. Nestlé, Giampiero Girolomoni, James G. Krueger
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman‐Yassky, Robert Bissonnette, Benjamin Ungar, Mayte Suárez‐Fariñas, Marius Ardeleanu, Hitokazu Esaki, Maria Suprun, Yeriel Estrada, Hui Xu, Xiangyu Peng, Jonathan I. Silverberg, Alan Menter, James G. Krueger, Rick Zhang, Usman Chaudhry, Brian N. Swanson, Neil M.H. Graham, Gianluca Pirozzi, George D. Yancopoulos, Jennifer D. Hamilton
A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci
Ying Liu, Cynthia Helms, Wilson Liao, Lisa C. Zaba, Shenghui Duan, Jennifer M. Gardner, Carol A. Wise, Andrew G. Miner, Mary J. Malloy, Clive R. Pullinger, John P. Kane, Scott F. Saccone, Jane Worthington, Ian N Bruce, Pui–Yan Kwok, Alan Menter, James G. Krueger, Anne Barton, Nancy L. Saccone, A. Bowcock
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen, Stacy Smith, Robert Matheson, Craig L. Leonardi, César A. Calderón, Carrie Brodmerkel, Katherine Li, Kim Campbell, Stanley J. Marciniak, Yasmine Wasfi, Yuhua Wang, Philippe Szapary, James G. Krueger